Projects

RNDr. Daniela Gašperíková, DrSc.
Scientific Director

International

Current
  • European Network for Sigma-1 Receptor as a Therapeutic Opportunity
    Program: COST
    Duration: 25. 10. 2024 – 24. 10. 2028
  • Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
    Program: Horizon Europe
    Duration: 1. 3. 2024 – 29. 2. 2028
Finished
  • Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe
    Program: Horizon 2020
    Duration: 1. 5. 2021 – 30. 4. 2024
  • Metabolic health and muscle secretory profile in aerobic and resistance trained obese pre-diabetic individuals
    Program: Multilateral - other
    Duration: 15. 2. 2010 – 14. 2. 2013
  • Adipose tissue and skeletal muscle plasticity in metabolic health and in insulin resistance
    Program: Multilateral - other
    Duration: 25. 1. 2010 – 24. 1. 2013
  • Lipid droplets as dynamic organelles of fat deposition and release: translational research towards human disease
    Program: FP7
    Duration: 1. 5. 2008 – 31. 10. 2012
  • Adipose tissue: A key target for prevention of the metabolic syndrome
    Program: COST
    Duration: 1. 6. 2007 – 31. 5. 2011

National

Current
  • The effect of pathologic mutations and post-translational modifications on the functions of mitochondrial processing peptidase essential for transport to mitochondria
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2028
  • Genetic causes of rare inherited metabolic diseases with emphasis on functional studies of novel variants
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Mutations associated with Wolfram syndrome: alternative signaling pathways for calcium and mitochondrial physiology
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Research of clinical and genetic aspects of ketotic hypoglycemia in children
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Infrastructure for the study of genetic causes of rare metabolic diseases
    Program:
    Duration: 1. 7. 2024 – 30. 6. 2025
  • Identification of novel genetic variants in syndromic hearing loss by whole exome sequencing
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Genetics of rare forms of diabetes with focus on functional characterization of new variants
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Identification of etiology in sporadic forms of hereditary hearing loss by whole exome sequencing
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Systemic public research institution - biobank for cancer and rare diseases
    Program:
    Duration: 1. 6. 2020 – 31. 12. 2023
  • Strengthening of research, development and innovation capacities of translational biomedical research of human diseases
    Program:
    Duration: 1. 1. 2020 – 30. 6. 2023
  • Genetic causes of rare diseases with emphasis on metabolic disorders associated with hypoglycemia and mitochondiopathies
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Comprehensive innovative diagnostics and personalized treatment of diabetes mellitus in children
    Program: Other projects
    Duration: 1. 10. 2019 – 31. 3. 2022
  • Diagnostic and pharmacogenetic aspects of monogenic diabetes type MODY
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Whole exome sequencing in patients with primary mitochondriopathies
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Identification of novel gene variants of hereditary hearing loss based on nationwide screening
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Whole exome sequencing in multiplex families with hereditary hearing loss in Slovakia: identification of novel gene variants
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Identification of new genetic aspects of monogenic endocrinopathies by next generation sequencing
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Molecular-genetic research with pharmacogenetic consequences in children with hyperinsulinemic hypoglycemia
    Program: SRDA
    Duration: 1. 10. 2013 – 31. 5. 2017
  • Prevalence and mutation spektrum of the most common forms of monogenic obesity
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • University Biomedical Research Park Bratislava
    Program: EU Structural Funds Research & Development
    Duration: 1. 7. 2013 – 31. 12. 2015
  • Implementation of molecular medicine into diagnostics, therapy and prevention of serious lifestyle diseases
    Program: EU Structural Funds Research & Development
    Duration: 30. 12. 2010 – 31. 1. 2014
  • Epidemiology and genetics of MODY subtypes in Slovakia
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Transfer of genetic knowledge of endocrine research into clinical praxis
    Program: EU Structural Funds Research & Development
    Duration: 1. 11. 2010 – 31. 8. 2013
  • Morphological-functional aspects of the adipose tissue in patients with chronic obstructive pulmonary disease (COPD)
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Centre of excellence for translational research in molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 11. 2010 – 31. 5. 2012
  • Genes which are increasing the risk to develop rheumatoid arthritis in the Austrian and Slovak populations
    Program: Other projects
    Duration: 1. 6. 2009 – 1. 1. 2012
  • Lipid droplets as dynamic organelles of fat deposition and release: translational research towards human disease
    Program: SRDA
    Duration: 1. 12. 2008 – 31. 12. 2011
  • Relationship between systemic inflammation, insulin resistance and cardiovascular risk in patients with obstructive sleep apnea
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Center of Excelence for Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 31. 5. 2011
  • Development of the Molecular Medicine Centre, SAS as a unique institution in modern medicine in Slovakia
    Program:
    Duration: 1. 7. 2009 – 30. 4. 2011
  • Centre of excellence for translational research in molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 19. 5. 2009 – 18. 4. 2011
  • Systemic inflammation and expression of cytokines in the adipose tissue in association with pulmonary functions in patients with the chronic obstructive pulmonary disease /COPD/
    Program: SRDA
    Duration: 1. 2. 2007 – 31. 12. 2009
  • Adipose tissue and innate inflammation in obese subjects and subjects with growth hormone deficiency
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
  • The role mitochondria and cytokines from the skeletal muscle and adipose tissue during the development of diet-induced obesity
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
  • Subclinical systemic inflammation in relationship to obstructive ventilatory impairment and cachexia in patients with chronic obstructive pulomnary disease
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
Employees